Clinical Trial Update: Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial of panobinostat in combination with everolimus for relapsed or refractory lymphoma or multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Afinitor (everolimus)
• Farydak (panobinostat)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: COMPLETED